: Researchers use small-scale platforms like the ambr®15 to simulate large-scale manufacturing conditions. 3. Define the Design Space
Used to remove DNA, endotoxins, and some HCPs.
Future optimization work will explore the transition toward an end-to-end continuous manufacturing platform. This includes testing continuous multi-column chromatography (MCC) for the Protein A capture step, which promises to reduce resin costs, minimize footprint, and further increase production throughput.
The was defined such that any combination within ranges (e.g., Protein A elution pH 3.6–4.0, polishing flow rate 150–250 cm/h) yielded CQA compliance. A Mab A Case Study In Bioprocess Development
If you would like to expand on a specific section of this case study, let me know: kLak sub cap L a or shear rates)?
The optimized bioprocess for mAb-A production yielded significant improvements:
The A-Mab study serves as a roadmap for applying guidelines to biotechnology. : Researchers use small-scale platforms like the ambr®15
The 2,000L harvest contained A Mab at 6.8 g/L, plus host cell proteins (HCPs), DNA, and cell debris. The train:
A process that works beautifully at a 2 L bench-top bioreactor may fail at a 2,000 L commercial scale. Small deviations in mixing, oxygen transfer, or heat dissipation can dramatically alter cell behavior and product quality. The key to successful is maintaining geometric, hydrodynamic, and mass-transfer similarity across scales.
Media formulation significantly impacts both titer and glycosylation. Future optimization work will explore the transition toward
Assessed using Cation Exchange Chromatography (CEX-HPLC) to profile acidic, main, and basic variants.
The harvest step removes cells and cellular debris from the bioreactor broth to deliver a clarified fluid suitable for chromatography.
The paper outlines the "lab bench to bedside" journey through four primary phases: A–Mab: A Case Study in Bioprocess Development - ISPE
New technologies are accelerating process development and control. The integration of and advanced analytics is enabling real-time monitoring and proactive process control, making processes smarter and more adaptive. Moreover, while most mAbs are produced in CHO cells, microbial systems are being explored as potentially cheaper and faster alternatives, though they face challenges in performing the complex post-translational modifications required for human therapeutic efficacy.